Company intelligence / Profile preview

Ibex Medical Analytics

Ownership: Private
Development stage: Commercial

Overview

Ibex’s Galen™ platform has demonstrated near-perfect concordance with expert pathologists in clinical studies. The company’s flagship product “Ibex Prostate Detect” received FDA 510(k) clearance in February 2025 as an aid for detecting small and rare prostatic cancers. Clinical deployments have shown improved accuracy of diagnosis, comprehensive quality control measures, reduced turnaround times, and productivity gains up to 37% when integrated into digital pathology workflows.

Therapeutic areas: Oncology
Modalities: Device
Industry: Pathology

Drug pipeline

4 assets

Galen Prostate

Commercial

Indications: Prostate cancer

3 more assets in the full pipeline.

Request access →

Partnerships

Philips (integration of AI tools into Philips IntelliSite Pathology Solution)Alverno LaboratoriesInstitut Curie

Beyond the preview

Go deeper on Ibex Medical Analytics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ibex Medical Analytics.

Explore the full profile